The global Breast Cancer Drugs Market is anticipated to gain lucrative growth over the forecast period owing to rising incidences of breast cancer and advent of novel therapies. Rising incidence of the disorder is the consequence of mutations in genetic profile of the patients, exposure to harmful radiations, unhealthy lifestyles, and rising female geriatric population. Advent of novel therapies such as Abraxane, Albumin-bound nanoparticle drugs, and Custirsen Sodium are expected to induce the demand for the market further.
Full research report on Global Minimally Invasive Surgery Market with detailed figures and charts available at:
The global breast cancer drugs market is segmented on the basis of treatment into surgery & radiation therapy, hormonal therapy, chemotherapy, and targeted therapy. As of 2014, chemotherapy held the largest share of the breast cancer drugs market as a consequence of rapid destruction and prevention of multiplication of cancer cells, thereby restricting the progression of disease. It was followed by surgery and radiation therapy owing to rising prevalence of complex patient profiles with shrunk tumors that are removable through surgery only. Targeted therapy is expected to be the fastest growing over the forecast period owing to benefits such as less collateral damage to surrounding tissue, less toxic levels, and localized action.
Get more information on Global Endoscopy Market or request for TOC of this research report at:
As of 2014, North America held the substantial share of global breast cancer drugs market due to factors such as rising incidences of breast cancer and increasing government welfare initiatives. Moreover, advanced healthcare infrastructure, increased awareness, and reimbursement policies are also responsible to induce the growth of this region. Asia Pacific is expected to be the fastest growing owing to factors such as rising investments, increasing disposable income, improving healthcare infrastructure, rising awareness regarding the early signs and methods of detection of breast cancer.
View more reports of this category by Grand View Research at:
The key market players include BioNumerik Pharmaceuticals, Bipar Sciences, Pfizer, Oncogenex, Novartis AG, Astellas, and Apthera Inc. These players employ strategies such as focusing on new product approvals and developing innovative products. Employment of strategic partnership, co-development, key licensing agreement, and targeting regions enable to lead the market. They emphasise on developing cost-efficient new drug pipelines that leads to expansion of their market share. For instance, Biocon launched a new injectable drug in 2014 for the treatment of the breast cancer, priced 25% less than other existing drugs in the market.
About Grand View Research
Grand View Research, Inc. is a market research and consulting company that provides off-the-shelf, customized research reports and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and energy. With a deep-seated understanding of varied business environments, Grand View Research provides strategic objective insights.
For more information, visit: http://www.grandviewresearch.com/
Company Name: Grand View Research, Inc.
Contact Person: Sherry James, Corporate Sales Specialist – U.S.A.
Email: firstname.lastname@example.org, email@example.com
Phone: 1-415-349-0058, Toll Free: 1-888-202-9519
Address:28 2nd Street, Suite 3036
City: San Francisco
Country: United States